ZFIN ID: ZDB-PUB-210307-7
Development of BCR-ABL1 Transgenic Zebrafish Model Reproducing Chronic Myeloid Leukemia (CML) Like-Disease and Providing a New Insight into CML Mechanisms
Zizioli, D., Bernardi, S., Varinelli, M., Farina, M., Mignani, L., Bosio, K., Finazzi, D., Monti, E., Polverelli, N., Malagola, M., Borsani, E., Borsani, G., Russo, D.
Date: 2021
Source: Cells   10(2): (Journal)
Registered Authors: Borsani, Giuseppe
Keywords: BCR-ABL1, UAS/hsp70-Gal4, chronic myeloid leukemia (CML), embryonic development, hematopoiesis, transgenic animal model, zebrafish
MeSH Terms:
  • Animals
  • Animals, Genetically Modified
  • Disease Models, Animal
  • Humans
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive/genetics*
  • Zebrafish
PubMed: 33669758 Full text @ Cells
FIGURES
ABSTRACT
Zebrafish has proven to be a versatile and reliable experimental in vivo tool to study human hematopoiesis and model hematological malignancies. Transgenic technologies enable the generation of specific leukemia types by the expression of human oncogenes under specific promoters. Using this technology, a variety of myeloid and lymphoid malignancies zebrafish models have been described. Chronic myeloid leukemia (CML) is a clonal myeloproliferative neoplasia characterized by the BCR-ABL1 fusion gene, derived from the t (9;22) translocation causing the Philadelphia Chromosome (Ph). The BCR-ABL1 protein is a constitutively activated tyrosine kinas inducing the leukemogenesis and resulting in an accumulation of immature leukemic cells into bone marrow and peripheral blood. To model Ph+ CML, a transgenic zebrafish line expressing the human BCR-ABL1 was generated by the Gal4/UAS system, and then crossed with the hsp70-Gal4 transgenic line. The new line named (BCR-ABL1pUAS:CFP/hsp70-Gal4), presented altered expression of hematopoietic markers during embryonic development compared to controls and transgenic larvae showed proliferating hematopoietic cells in the caudal hematopoietic tissue (CHT). The present transgenic zebrafish would be a robust CML model and a high-throughput drug screening tool.
ADDITIONAL INFORMATION